CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MetaStat Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MetaStat Inc
27 Drydock Ave., 2Nd Floor
Phone: (212) 796-8170p:212 796-8170 BOSTON, MA  02210  United States Ticker: MTSTMTST
This company ceased filing statements with the SEC on 7/16/2018.
Business Summary
MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
2/28/20182/28/2018YesYes---

Industries
SIC Code Description
3674 Semiconductors and related devices
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Jerome B.Zeldis 73 5/3/2017 4/25/2016
President, Chief Executive Officer, Director Douglas A.Hamilton 52 5/3/2017 6/17/2015
Vice President - Finance Daniel H.Schneiderman 44 1/1/2018 12/21/2012
Director Paul R.Billings 66 5/24/2017 5/24/2017

Business Names
Business Name
MetaStat BioMedical, Inc.
MetaStat, Inc.
MTST
Photovoltaic Solar Cells Inc(NDA)

General Information
Number of Employees: 6 (As of 2/28/2014)
Outstanding Shares: 5,877,383 (As of 5/18/2018)
Shareholders: 130
Stock Exchange: OTC
Federal Tax Id: 208753132


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023